Curevac has been granted a patent for a composition comprising mRNA encoding a SARS-CoV-2 spike protein and a lipid nanoparticle. The invention aims to treat or prevent coronavirus infections, particularly COVID-19. The composition includes specific stabilizing mutations and substitutions in the spike protein sequence. GlobalData’s report on Curevac gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Curevac NV - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Curevac, Personalized cancer vaccines was a key innovation area identified from patents. Curevac's grant share as of February 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Composition for covid-19 mrna vaccine in lipid nanoparticle

Source: United States Patent and Trademark Office (USPTO). Credit: Curevac NV

A recently granted patent (Publication Number: US11918643B2) discloses a composition for treating or preventing a disorder, particularly related to SARS-CoV-2. The composition includes an mRNA encoding a pre-fusion stabilized spike protein of the virus, complexed with a lipid nanoparticle (LNP) containing specific components in defined molar ratios. The mRNA sequences contain various stabilizing mutations and amino acid substitutions, along with heterologous untranslated regions (UTR) and poly(A) sequences, ensuring efficient delivery and expression of the spike protein.

Furthermore, the patent covers compositions with specific G/C content, sequences derived from known genes for UTRs, histone stem-loops, and nucleotide analog substitutions like pseudouridine. The mRNA integrity is maintained through purification methods, and the LNPs have a defined size range and lipid to RNA molar ratio. The patent also includes provisions for a kit containing the composition and instructions for use, as well as a method for treating or preventing disorders by administering the disclosed composition to individuals in need. These claims highlight the detailed and specific nature of the composition, emphasizing its potential in therapeutic applications related to SARS-CoV-2 and other disorders.

To know more about GlobalData’s detailed insights on Curevac, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies